Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Docetaxel 19pembrolizumab 14Surveys and Questionnaires 7Radiotherapy 7Paclitaxel 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Standard of Care 6Specimen Handling 6Radiosurgery 6Psychiatric Rehabilitation 6Early Intervention, Educational 6Trastuzumab 5Nivolumab 5enzalutamide 4Interviews as Topic 4motexafin gadolinium 3cabozantinib 3X-Rays 3Sirolimus 3Methods 3Educational Status 3Cisplatin 3Carboplatin 3Azacitidine 3tisotumab vedotin 2rucaparib 2pertuzumab 2pegilodecakin 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × mocetinostat × Thoracic × Clear all
NCT00511576 2015-01-08

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Mirati Therapeutics Inc.

Phase 1 Terminated
54 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡